{"id":30336,"date":"2025-01-31T16:20:04","date_gmt":"2025-01-31T21:20:04","guid":{"rendered":"https:\/\/www.ipoboutique.com\/blog\/?p=30336"},"modified":"2025-01-31T16:20:04","modified_gmt":"2025-01-31T21:20:04","slug":"ipo-summary-beta-bionics-metsera-mark-major-winners-in-ipo-market-rebound","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/ipo-summary-beta-bionics-metsera-mark-major-winners-in-ipo-market-rebound\/","title":{"rendered":"IPO Summary: Beta Bionics, Metsera mark major winners in IPO Market Rebound"},"content":{"rendered":"<p><strong>Following the disappointing debut of Venture Global (VG), the IPO market needed a boost and got it in the healthcare sector.<\/strong><\/p>\n<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125.jpg\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-30337\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125-300x29.jpg\" alt=\"\" width=\"300\" height=\"29\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125-300x29.jpg 300w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125-1024x99.jpg 1024w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125-768x74.jpg 768w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125-600x58.jpg 600w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2025\/01\/iposumm013125.jpg 1497w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p><strong>Beta Bionics Inc. (BBNX)<\/strong>, a company that developed a device to improve the health and quality of life of insulin-dependent individuals with diabetes,<strong>\u00a0priced 12.0 million shares at $17.00<\/strong>\u2014both the size and price were revised upward from its original terms. The stock\u00a0<strong>opened 29.4% above<\/strong>\u00a0its issue price at $22.00 and closed its debut session at $23.63,\u00a0<strong>delivering a first-day gain of 39.0%.<\/strong><\/p>\n<p><strong>Metsera (MTSR)<\/strong>\u00a0priced 15.3mm shares (downsized from 17.2mm) at $18.00 ($1 above the range) and opened at $25.50 for a <strong>gain of 41.3% at first trade.<\/strong> We have never seen a biotech IPO downsize its IPO while pricing its transaction above range. Turns out, the company was seeking a specific cash-raise of $275 million and was not looking to allow further dilution. In our opinion this attributed to the &#8220;explosiveness&#8221; on day one.<\/p>\n<p>Throughout the week, Infinity Natural Resources had to manage the\u00a0<strong>Venture Global (VG)<\/strong>\u00a0headwind &#8212; a previously broken IPO from the energy sector.\u00a0<strong>VG<\/strong> traded more than 20% below issue while the Infinity team was on the road with investors. Ultimately, <strong>Infinity Natural Resources Inc. (INR)\u00a0<\/strong>priced a full-size deal of 13.25mm shares at $20.00 (upper-half of the range) and\u00a0<strong>opened at $22.16 for a gain of 11.3% at first trade.<\/strong><\/p>\n<p><strong>Smithfield Foods Inc. (SFD)<\/strong> reworked its IPO terms at the eleventh hour and it still was not enough to hold issue on day one. The company priced a<strong>\u00a0downsized transaction of 26.08mm shares (down from 34.8mm) at $20.00<\/strong>\u00a0(original range $23-$27) and\u00a0<strong>opened at $21.05 for a gain of 5.3% at first trade<\/strong>. The stock was met with heavy selling pressure in the first fifteen minutes of trading as investors scrambled to the exit.\u00a0<strong>Within an hour, the stock had broke its $20.00 issue price.\u00a0<\/strong>It should be noted that SFD rebounded in subsequent sessions and was able to close the week in the black with<strong> a final Friday print of $21.50.<\/strong><\/p>\n<p><strong>Maze Therapeutics (MAZE)<\/strong>\u00a0priced 8.75mm shares (upsized from 7.85mm) at the midpoint of the range, $16.00, and<strong>\u00a0opened at $16.12 for a gain of 0.8% at first trade.<\/strong>\u00a0The stock traded as high as $17.00 in the first minute of trading before retreating to the issue price and trading steady the remainder of the day.\u00a0<strong>We find this outcome particularly concerning<\/strong>\u00a0as the underwriters\u00a0<strong>felt the need to upsize<\/strong>\u00a0the deal but could not provide those buyers much of a premium at first trade versus issue price.<\/p>\n<p>There was a BDC on the schedule this week, <b>MSC Income Fund, Inc. (MSIF), <\/b>\u00a0which priced 5.5mm shares at $15.53 and opened at $15.43 for a loss of\u00a0 0.6% at first trade.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following the disappointing debut of Venture Global (VG), the IPO market needed a boost and got it in the healthcare sector. Beta Bionics Inc. (BBNX), a company that developed a device to improve the health and quality of life of insulin-dependent individuals with diabetes,\u00a0priced 12.0 million shares at $17.00\u2014both the size and price were revised[&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":null,"zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":null,"zakra_breadcrumbs_separator_color":null,"zakra_breadcrumbs_link_color":null,"zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1536],"tags":[],"class_list":["post-30336","post","type-post","status-publish","format-standard","hentry","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/30336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=30336"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/30336\/revisions"}],"predecessor-version":[{"id":30338,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/30336\/revisions\/30338"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=30336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=30336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=30336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}